Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
2024 WS
Vergangene Veranstaltungen (max. 10)
-
2024 SS
- Arbeiten in den Laboratorien der Inneren Klinik (Tumorforschung)
- Blockpraktikum Innere Medizin (PV)
- Hämatologisches und onkologisches Mittagsseminar
- Wahlpflichtmodul Innere Medizin (Studiengang Med. Biologie)
- E3 - Med - Cancer Biology - Cr. 3-3
- Molekulare Onkologie
- Wahlfach: Cancer Biology
- Differentialdiagnose Innere Krankheiten
-
2023 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical TherapyIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 6, S. 880 - 887Online Volltext: dx.doi.org/
-
Are histomorphological patterns a predictor for survival in uveal melanoma patients with hepatic metastases undergoing hepatic artery infusion chemotherapy?In: Journal of Medical Imaging and Radiation Oncology (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
Cell-mediated cytotoxicity within CSF and brain parenchyma in spinal muscular atrophy unaltered by nusinersen treatmentIn: Nature Communications Jg. 15 (2024) Nr. 1, 4120Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
CellViT : Vision Transformers for precise cell segmentation and classificationIn: Medical Image Analysis Jg. 94 (2024) 103143Online Volltext: dx.doi.org/ (Open Access)
-
Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy : a pooled analysis of five clinical trials from two decades of the German AIO study groupIn: ESMO Open Jg. 9 (2024) Nr. 4, 102944Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to “Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: (NEOLAP-AIO-PAK-0113)” : results from a prospective, multicenter phase II trialIn: ESMO Open Jg. 9 (2024) Nr. 5, 103463Online Volltext: dx.doi.org/ (Open Access)
-
Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided OptimizationIn: ACS Chemical Biology Jg. 19 (2024) Nr. 2, S. 266 - 279Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Diagnostic Accuracy of ⁶⁸Ga-FAPI Versus ¹⁸F-FDG PET in Patients with Various MalignanciesIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 3, S. 372 - 378Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein α-Directed Imaging and Therapy of Solitary Fibrous TumorIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 2, S. 252 - 257Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein-Directed Imaging Outperforms ¹⁸F-FDG PET/CT in Malignant Mesothelioma : A Prospective, Single-Center, Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 8, S. 1188 - 1193Online Volltext: dx.doi.org/
-
Head-to-head comparison of ⁶⁸ Ga-FAPI-46 PET/CT, ¹⁸F-FDG PET/CT, and contrast-enhanced CT for the detection of various tumorsIn: Annals of Nuclear Medicine (2024) in pressOnline Volltext: dx.doi.org/
-
Histology-Based Radiomics for [¹⁸F]FDG PET Identifies Tissue Heterogeneity in Pancreatic CancerIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 7, S. 1151 - 1159Online Volltext: dx.doi.org/ (Open Access)
-
Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009–2021In: Cancer Epidemiology Jg. 93 (2024) 102659Online Volltext: dx.doi.org/ (Open Access)
-
METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer : Multimodal surgical treatment versus systemic chemotherapy alone: A prospective randomized controlled multicenter phase III trialIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. Suppl. 16, TPS4207Online Volltext: dx.doi.org/
-
Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell-free RNAIn: Molecular Oncology (2024) in pressOnline Volltext: dx.doi.org/ (Open Access)
-
P-move : A randomized control trial of exercise in patients with advanced pancreatic or biliary tract cancer (aPBC) receiving beyond first-line chemotherapyIn: Supportive Care in Cancer Jg. 32 (2024) Nr. 7, 437Online Volltext: dx.doi.org/ (Open Access)
-
Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylationIn: Clinical Epigenetics Jg. 16 (2024) Nr. 1, 13Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic Implications of ⁶⁸Ga-FAPI-46 PET/CT-Derived Parameters on Overall Survival in Various Types of Solid TumorsIn: Journal of Nuclear Medicine (JNM) Jg. 65 (2024) Nr. 7, S. 1027 - 1034Online Volltext: dx.doi.org/
-
Prognostic value of deep learning-derived body composition in advanced pancreatic cancer : A retrospective multicenter studyIn: ESMO Open Jg. 9 (2024) Nr. 1, 102219Online Volltext: dx.doi.org/ (Open Access)
-
Stroke and myocardial infarction induce neutrophil extracellular trap release disrupting lymphoid organ structure and immunoglobulin secretionIn: Nature Cardiovascular Research Jg. 3 (2024) Nr. 5, S. 525 - 540Online Volltext: dx.doi.org/ (Open Access)
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics Jg. 14 (2024) Nr. 14, S. 5400 - 5412Online Volltext: dx.doi.org/ (Open Access)
-
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer : Is it really a valid tool for patient selection?In: Clinical and Translational Oncology Jg. 26 (2024) Nr. 5, S. 1268 - 1272Online Volltext: dx.doi.org/ (Open Access)
-
Understanding homologous recombination repair deficiency in biliary tract cancers : clinical implications and correlation with platinum sensitivityIn: ESMO Open Jg. 9 (2024) Nr. 8, 103630Online Volltext: dx.doi.org/ (Open Access)
-
[⁶⁸Ga]Ga-FAPI versus 2-[¹⁸F]FDG PET/CT in patients with autoimmune thyroiditis : A case control studyIn: EJNMMI Research Jg. 14 (2024) Nr. 1, 66Online Volltext: dx.doi.org/ (Open Access)
-
68Ga-Labeled Fibroblast Activation Protein Inhibitor (⁶⁸Ga-FAPI) PET for Pancreatic Adenocarcinoma : Data from the ⁶⁸Ga-FAPI PET Observational TrialIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 12, S. 1910 - 1917Online Volltext: dx.doi.org/ (Open Access)
-
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO)In: Oncology Research and Treatment Jg. 46 (2023) Nr. 3, S. 89 - 99Online Volltext: dx.doi.org/
-
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in GlioblastomaIn: Clinical Cancer Research Jg. 29 (2023) Nr. 2, S. 488 - 500Online Volltext: dx.doi.org/ (Open Access)
-
A prognostic systemic inflammation score (SIS) in patients with advanced intrahepatic cholangiocarcinomaIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 8, S. 5085 - 5094Online Volltext: dx.doi.org/ (Open Access)
-
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer : MORPHEUS Phase Ib/II Umbrella Randomized Study PlatformIn: The Oncologist Jg. 28 (2023) Nr. 6, S. 553 - e472Online Volltext: dx.doi.org/ (Open Access)
-
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy ProtocolsIn: Oncology Research and Treatment Jg. 46 (2023) Nr. 4, S. 140 - 150Online Volltext: dx.doi.org/
-
Coinhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcriptionIn: Science Advances Jg. 9 (2023) Nr. 41, eadg5109Online Volltext: dx.doi.org/ (Open Access)
-
Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cellsIn: British Journal of Haematology Jg. 202 (2023) Nr. 5, S. 1033 - 1048Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein Inhibitor Theranostics : The Case for Use in SarcomaIn: PET Clinics Jg. 18 (2023) Nr. 3, S. 361 - 367Online Volltext: dx.doi.org/
-
Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal AdenocarcinomaIn: Molecular Pharmaceutics Jg. 20 (2023) Nr. 8, S. 4319 - 4330Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast Activation Protein-Targeting Minibody-IRDye700DX for Ablation of the Cancer-Associated Fibroblast with Photodynamic TherapyIn: Cells Jg. 12 (2023) Nr. 10, 1420Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 5, S. 711 - 716Online Volltext: dx.doi.org/ (Open Access)
-
Histology-Based Prediction of Therapy Response to Neoadjuvant Chemotherapy for Esophageal and Esophagogastric Junction Adenocarcinomas Using Deep LearningIn: JCO Clinical Cancer Informatics (JCO CCI) Jg. 7 (2023) S. e2300038Online Volltext: dx.doi.org/ (Open Access)
-
Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 8, S. 4315 - 4325Online Volltext: dx.doi.org/ (Open Access)
-
Identification of a ΔNp63-Dependent Basal-Like A Subtype-Specific Transcribed Enhancer Program (B-STEP) in Aggressive Pancreatic Ductal AdenocarcinomaIn: Molecular Cancer Research Jg. 21 (2023) Nr. 9, S. 881 - 891Online Volltext: dx.doi.org/ (Open Access)
-
Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh®TM) Methodology : A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic CancerIn: Current Oncology Jg. 30 (2023) Nr. 6, S. 5828 - 5834Online Volltext: dx.doi.org/ (Open Access)
-
Interactive enhancer hubs (iHUBs) mediate transcriptional reprogramming and adaptive resistance in pancreatic cancerIn: Gut Jg. 72 (2023) Nr. 6, S. 1174 - 1185Online Volltext: dx.doi.org/
-
LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer GrowthIn: Clinical Cancer Research Jg. 29 (2023) Nr. 6, S. 1137 - 1154Online Volltext: dx.doi.org/
-
Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancerIn: Nature Jg. 615 (2023) Nr. 7950, S. 168 - 174Online Volltext: dx.doi.org/ (Open Access)
-
Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotypeIn: Gut Jg. 72 (2023) Nr. 3, S. 522 - 534Online Volltext: dx.doi.org/ (Open Access)
-
Novel ⁶⁸Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19 Vaccine-Related PitfallsIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 3, S. 368 - 371Online Volltext: dx.doi.org/ (Open Access)
-
Oncologic Staging with ⁶⁸Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than ¹⁸F-FDG PET/CTIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 12, S. 1906 - 1909Online Volltext: dx.doi.org/ (Open Access)
-
Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafuspIn: European Journal of Cancer (EJC) Jg. 191 (2023) 112986Online Volltext: dx.doi.org/ (Open Access)
-
Precision neuro-oncology : A pilot analysis of personalized treatment in recurrent gliomaIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 7, S. 3513 - 3526Online Volltext: dx.doi.org/ (Open Access)
-
Protocol of the IntenSify-Trial : An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacyIn: Clinical and Translational Science (CTS) Jg. 16 (2023) Nr. 12, S. 2483 - 2493Online Volltext: dx.doi.org/ (Open Access)
-
SOX2 dosage sustains tumor-promoting inflammation to drive disease aggressiveness by modulating the FOSL2/IL6 axisIn: Molecular Cancer Jg. 22 (2023) Nr. 1, 52Online Volltext: dx.doi.org/ (Open Access)
-
Smaller panel, similar results : Genomic profiling and molecularly informed therapy in pancreatic cancerIn: ESMO Open Jg. 8 (2023) Nr. 3, 101539Online Volltext: dx.doi.org/ (Open Access)
-
Superior Tumor Detection for ⁶⁸Ga-FAPI-46 Versus ¹⁸F-FDG PET/CT and Conventional CT in Patients with CholangiocarcinomaIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. 7, S. 1049 - 1055Online Volltext: dx.doi.org/ (Open Access)
-
Tebentafusp in Patients with Metastatic Uveal Melanoma : A Real-Life Retrospective Multicenter StudyIn: Cancers Jg. 15 (2023) Nr. 13, 3430Online Volltext: dx.doi.org/ (Open Access)
-
Bcl-x(L) as prognostic marker and potential therapeutic target in cholangiocarcinomaIn: Liver International Jg. 42 (2022) Nr. 12, S. 2855 - 2870Online Volltext: dx.doi.org/ (Open Access)
-
Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotypeIn: Clinical and Translational Medicine Jg. 12 (2022) Nr. 11, e1090Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Combined multimodal ctDNA analysis and radiological imaging for tumor surveillance in Non-small cell lung cancerIn: Translational Oncology Jg. 15 (2022) Nr. 1, 101279Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersIn: Annals of Oncology Jg. 33 (2022) Nr. 11, S. 1186 - 1199Online Volltext: dx.doi.org/ (Open Access)
-
Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients with Resectable or Borderline Resectable Disease (COMM-PACT-RB) : A Systematic Review and Delphi Consensus StatementIn: JAMA Oncology Jg. 8 (2022) Nr. 6, S. 929 - 937Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group Molecular Diagnostics and Therapy”In: European Journal of Cancer (EJC) Jg. 162 (2022) S. 245 - 246Online Volltext: dx.doi.org/
-
Das Pankreaskarzinom : Klinische Projekte der onkologischen Studiengruppen in Deutschland (ACO, AIO und ARO)In: Der Onkologe Jg. 28 (2022) Nr. Suppl. 1, S. 30 - 35Online Volltext: dx.doi.org/
-
Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2022) Nr. 1, S. 115 - 129Online Volltext: dx.doi.org/ (Open Access)
-
Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinomaIn: Cancer & Metabolism Jg. 10 (2022) Nr. 1, 24Online Volltext: dx.doi.org/ (Open Access)
-
Gene expression-based prediction of pazopanib efficacy in sarcomaIn: European Journal of Cancer (EJC) Jg. 172 (2022) S. 107 - 118Online Volltext: dx.doi.org/
-
Initial Clinical Experience with ⁹⁰Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors : A Case Series of 9 PatientsIn: Journal of Nuclear Medicine (JNM) Jg. 63 (2022) Nr. 5, S. 727 - 734Online Volltext: dx.doi.org/ (Open Access)
-
MCL1 as putative target in pancreatoblastomaIn: Virchows Archiv Jg. 481 (2022) Nr. 2, S. 265 - 272Online Volltext: dx.doi.org/ (Open Access)
-
Multimodal survival prediction in advanced pancreatic cancer using machine learningIn: ESMO Open Jg. 7 (2022) Nr. 5, 100555Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PET-directed combined modality therapy for gastroesophageal junction cancer : Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK)In: European Journal of Cancer (EJC) Jg. 175 (2022) S. 99 - 106Online Volltext: dx.doi.org/
-
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer : A randomized phase-II study - The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510In: International Journal of Cancer Jg. 150 (2022) Nr. 6, S. 1007 - 1017Online Volltext: dx.doi.org/ (Open Access)
-
Pivotal antitumor role of the immune checkpoint molecule B7-H1 in pancreatic cancerIn: OncoImmunology Jg. 11 (2022) Nr. 1, 2043037Online Volltext: dx.doi.org/ (Open Access)
-
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases : translational results from the German multicenter AIO-YMO-PAK-0515 studyIn: ESMO Open Jg. 7 (2022) Nr. 1, 100388Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy : results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)In: ESMO Open Jg. 7 (2022) Nr. 4, 100552Online Volltext: dx.doi.org/ (Open Access)
-
Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expressionIn: Nature Communications Jg. 13 (2022) Nr. 1, 156Online Volltext: dx.doi.org/ (Open Access)
-
Radiation Dose Aspects of Hepatic Artery Infusion Chemotherapy in Uveal Melanoma Patients with Liver MetastasesIn: Cardiovascular and Interventional Radiology Jg. 45 (2022) Nr. 6, S. 841 - 845Online Volltext: dx.doi.org/ (Open Access)
-
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesIn: Clinical Cancer Research Jg. 28 (2022) Nr. 19, S. 4346 - 4353Online Volltext: dx.doi.org/ (Open Access)
-
The clinical utility of cfRNA for disease detection and surveillance : A proof of concept study in non-small cell lung cancerIn: Thoracic Cancer (2022) in pressOnline Volltext: dx.doi.org/ Online Volltext (Open Access)
-
⁶⁸Ga]FAPI-PET/CT for radiation therapy planning in biliary tract, pancreatic ductal adeno-, and adenoidcystic carcinomasIn: Scientific Reports Jg. 12 (2022) Nr. 1, 16261Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
A BAP1 synonymous mutation results in exon skipping, loss of function and worse patient prognosisIn: iScience Jg. 24 (2021) Nr. 3, 102173Online Volltext: dx.doi.org/ (Open Access)
-
Antitumor immune response is associated with favorable survival in GEP-NEN G3In: Endocrine-Related Cancer Jg. 28 (2021) Nr. 10, S. 683 - 693Online Volltext: dx.doi.org/
-
Author Correction: Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCCIn: Scientific Reports Jg. 11 (2021) Nr. 1, 11705Online Volltext: dx.doi.org/ (Open Access)
-
Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodelingIn: Journal of Nuclear Cardiology Jg. 28 (2021) Nr. 3, S. 812 - 821Online Volltext: dx.doi.org/ (Open Access)
-
Cellular model system to dissect the isoform-selectivity of Akt inhibitorsIn: Nature Communications Jg. 12 (2021) Nr. 1, 5297Online Volltext: dx.doi.org/ (Open Access)
-
Combined systemic inflammation score (SIS) correlates with prognosis in patients with advanced pancreatic cancer receiving palliative chemotherapyIn: Journal of Cancer Research and Clinical Oncology Jg. 147 (2021) Nr. 2, S. 579 - 591Online Volltext: dx.doi.org/ (Open Access)
-
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersIn: Cancer Discovery Jg. 11 (2021) Nr. 11, S. 2780 - 2795Online Volltext: dx.doi.org/ (Open Access)
-
Duktales Adenokarzinom des Pankreas : Entstehung, Diagnostik, TherapieIn: Der Gastroenterologe Jg. 16 (2021) Nr. 1, S. 41 - 50Online Volltext: dx.doi.org/
-
Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC) : A post hoc analysis of NAPOLI-1In: Pancreatology Jg. 21 (2021) Nr. 1, S. 192 - 199Online Volltext: dx.doi.org/ (Open Access)
-
Ecg scoring for the evaluation of therapy-naïve cancer patients to predict cardiotoxicityIn: Cancers Jg. 13 (2021) Nr. 6, S. 1197Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Hyperpolarized ¹³C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCCIn: Scientific Reports Jg. 11 (2021) Nr. 1, 1191Online Volltext: dx.doi.org/ (Open Access)
-
Laktatdehydrogenase vor transarterieller hepatischer Chemoperfusion prognostiziert das Überleben und den Tumorprogress bei Patienten mit Lebermetastasen bei AderhautmelanomIn: RöFo: Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren Jg. 193 (2021) Nr. 06, S. 683 - 691Online Volltext: dx.doi.org/ (Open Access)
-
Localized Angiosarcoma, Not One Disease : A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and EtiologyIn: Sarcoma Jg. 2021 (2021) 9960085Online Volltext: dx.doi.org/ (Open Access)
-
MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-IIn: Nature Communications Jg. 12 (2021) Nr. 1, 5505Online Volltext: dx.doi.org/ (Open Access)
-
Monosomy 3 is linked to resistance to mek inhibitors in uveal melanomaIn: International Journal of Molecular Sciences (IJMS) Jg. 22 (2021) Nr. 13, 6727Online Volltext: dx.doi.org/ (Open Access)
-
Multimodale Therapie ampullärer KarzinomeIn: Der Chirurg Jg. 92 (2021) Nr. 9, S. 803 - 808Online Volltext: dx.doi.org/
-
Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113) : a multicentre, randomised, phase 2 trialIn: The Lancet Gastroenterology & Hepatology Jg. 6 (2021) Nr. 2, S. 128 - 138Online Volltext: dx.doi.org/
-
Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinomaIn: EJNMMI Research Jg. 11 (2021) Nr. 1, 120Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Poly(ADP-ribose) polymerase inhibition in pancreatic cancerIn: Genes, Chromosomes and Cancer Jg. 60 (2021) Nr. 5, S. 373 - 384Online Volltext: dx.doi.org/ (Open Access)
-
Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusionIn: Radiology and Oncology Jg. 55 (2021) Nr. 3, S. 347 - 353Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer modelsIn: Genome Medicine Jg. 13 (2021) Nr. 1, 116Online Volltext: dx.doi.org/ (Open Access)
-
Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasisIn: Cell Reports Jg. 37 (2021) Nr. 8, 110056Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
The Latest Developments in Imaging of Fibroblast Activation ProteinIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. 2, S. 160 - 167Online Volltext: dx.doi.org/ (Open Access)
-
The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastomaIn: Cell Death and Disease Jg. 12 (2021) Nr. 10, 885Online Volltext: dx.doi.org/ (Open Access)
-
The predictive and prognostic significance of cell-free DNA concentration in melanomaIn: Journal of the European Academy of Dermatology and Venereology Jg. 35 (2021) Nr. 2, S. 387 - 395Online Volltext: dx.doi.org/ (Open Access)
-
Tumor-associated hematopoietic stem and progenitor cells positively linked to glioblastoma progressionIn: Nature Communications Jg. 12 (2021) Nr. 1, 3895Online Volltext: dx.doi.org/ (Open Access)
-
[¹⁸F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinomaIn: EJNMMI Research Jg. 11 (2021) Nr. 1, 70Online Volltext: dx.doi.org/ (Open Access)
-
Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemiaIn: Therapeutic Advances in Hematology Jg. 11 (2020) S. 1 - 15Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinomaIn: International Journal of Cancer Jg. 147 (2020) Nr. 10, S. 2847 - 2861Online Volltext: dx.doi.org/ (Open Access)
-
Conceptual framework for precision cancer medicine in Germany : Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’In: European Journal of Cancer (EJC) Jg. 135 (2020) S. 1 - 7Online Volltext: dx.doi.org/
-
Duktales Adenokarzinom des Pankreas : Entstehung, Diagnostik, TherapieIn: Der Onkologe Jg. 26 (2020) Nr. 10, S. 977 - 985Online Volltext: dx.doi.org/
-
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancerIn: Cell Death and Disease Jg. 11 (2020) Nr. 10, 875Online Volltext: dx.doi.org/ (Open Access)
-
Image-Based Molecular Phenotyping of Pancreatic Ductal AdenocarcinomaIn: Journal of Clinical Medicine (JCM) Jg. 9 (2020) Nr. 3, 724Online Volltext: dx.doi.org/ (Open Access)
-
Implementing cell-free DNA of pancreatic cancer patient–derived organoids for personalized oncologyIn: JCI Insight Jg. 5 (2020) Nr. 15, S. e137809Online Volltext: dx.doi.org/ (Open Access)
-
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer : Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 TrialIn: Pancreas Jg. 49 (2020) Nr. 1, S. 62 - 75Online Volltext: dx.doi.org/ (Open Access)
-
Loss of Wasl improves pancreatic cancer outcomeIn: JCI Insight Jg. 5 (2020) Nr. 10, e127275Online Volltext: dx.doi.org/ (Open Access)
-
Mir34a constrains pancreatic carcinogenesisIn: Scientific Reports Jg. 10 (2020) Nr. 1, S. 9654Online Volltext: dx.doi.org/ (Open Access)
-
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastomaIn: Scientific Reports Jg. 10 (2020) Nr. 1, S. 7157Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic : Are There Any Concerns?In: Journal of Nuclear Medicine (JNM) Jg. 61 (2020) Nr. 8, S. 1094 - 1095Online Volltext: dx.doi.org/ (Open Access)
-
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)In: International Journal of Cancer Jg. 147 (2020) Nr. 9, S. 2493 - 2502Online Volltext: dx.doi.org/ (Open Access)
-
Plasma next generation sequencing and droplet digital-qpcr-based quantification of circulating cell-free rna for noninvasive early detection of cancerIn: Cancers Jg. 12 (2020) Nr. 2, S. 353Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Proton Irradiation Increases the Necessity for Homologous Recombination Repair Along with the Indispensability of Non-Homologous End JoiningIn: Cells Jg. 9 (2020) Nr. 4, S. 889Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Serial Circulating Tumor DNA Mutational Status in Patients with KRAS-Mutant Metastatic Colorectal Cancer from the Phase 3 AIO KRK0207 TrialIn: Clinical Chemistry Jg. 66 (2020) Nr. 12, S. 1510 - 1520Online Volltext: dx.doi.org/ (Open Access)
-
TFEB-mediated lysosomal biogenesis and lysosomal drug sequestration confer resistance to MEK inhibition in pancreatic cancerIn: Cell Death Discovery Jg. 6 (2020) Nr. 1, 12Online Volltext: dx.doi.org/ (Open Access)
-
The transcription factor FLI1 promotes cancer progression by affecting cell cycle regulationIn: International Journal of Cancer Jg. 147 (2020) Nr. 1, S. 189 - 201Online Volltext: dx.doi.org/ (Open Access)
-
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinomaIn: Oncogene Jg. 39 (2020) Nr. 24, S. 4770 - 4779Online Volltext: dx.doi.org/ (Open Access)
-
A Novel Approach for Image-Guided I Therapy of Pancreatic Ductal Adenocarcinoma Using Mesenchymal Stem Cell-Mediated NIS Gene DeliveryIn: Molecular Cancer Research Jg. 17 (2019) Nr. 1, S. 310 - 320Online Volltext: dx.doi.org/ (Open Access)
-
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapyIn: PLoS ONE Jg. 14 (2019) Nr. 10, S. e0218642Online Volltext: dx.doi.org/ (Open Access)
-
A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imagingIn: European Radiology Experimental Jg. 3 (2019) Nr. 1, 41Online Volltext: dx.doi.org/ (Open Access)
-
Covalent-Allosteric Inhibitors to Achieve Akt Isoform-SelectivityIn: Angewandte Chemie International Edition Jg. 58 (2019) Nr. 52, S. 18823 - 18829Online Volltext: dx.doi.org/ (Open Access)
-
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer : a subgroup analysis of the pivotal NAPOLI-1 trialIn: Journal of Geriatric Oncology Jg. 10 (2019) Nr. 3, S. 427 - 435Online Volltext: dx.doi.org/ (Open Access)
-
MEK Inhibition Targets Cancer Stem Cells and Impedes Migration of Pancreatic Cancer Cells In Vitro and In VivoIn: Stem Cells International Jg. 2019 (2019) S. 8475389Online Volltext: dx.doi.org/ (Open Access)
-
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer : Final overall survival analysis and characteristics of long-term survivorsIn: European Journal of Cancer (EJC) Jg. 108 (2019) S. 78 - 87Online Volltext: dx.doi.org/ (Open Access)
-
Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers : pooled data from three independent cohortsIn: Clinical and Translational Oncology Jg. 21 (2019) Nr. 8, S. 1108 - 1111Online Volltext: dx.doi.org/
-
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic CancerIn: Cancers Jg. 11 (2019) Nr. 8, S. 1068Online Volltext: dx.doi.org/ (Open Access)
-
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal CancerIn: Cancer Research Jg. 79 (2019) Nr. 9, S. 2367 - 2378Online Volltext: dx.doi.org/
-
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorinIn: European Journal of Cancer (EJC) Jg. 106 (2019) S. 24 - 33Online Volltext: dx.doi.org/ (Open Access)
-
Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma CellsIn: Journal of Investigative Dermatology Jg. 139 (2019) Nr. 12, S. 2506 - 2516.e10Online Volltext: dx.doi.org/ (Open Access)
-
18F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancerIn: OncoTarget Jg. 9 (2018) Nr. 11, S. 10128 - 10134Online Volltext: dx.doi.org/ (Open Access)
-
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseIn: The Lancet Oncology Jg. 19 (2018) Nr. 3, S. e151 - e160Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 5, S. v42 - v43Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX : A prospective phase II study of the ‘Arbeitsgemeinschaft Internistische Onkologie’In: European Journal of Cancer (EJC) Jg. 94 (2018) S. 95 - 103Online Volltext: dx.doi.org/
-
Epigenetics of gastrointestinal diseases : notes from a workshopIn: Epigenetics Jg. 13 (2018) Nr. 4, S. 449 - 457Online Volltext: dx.doi.org/ (Open Access)
-
Fibroblast-activating protein : Targeting the roots of the tumor microenvironmentIn: Journal of Nuclear Medicine (JNM) Jg. 59 (2018) Nr. 9, S. 1412 - 1414Online Volltext: dx.doi.org/ (Open Access)
-
Immunotherapy and Combination Strategies in Pancreatic Cancer : Current Status and Emerging TrendsIn: Oncology Research and Treatment Jg. 41 (2018) Nr. 5, S. 286 - 290Online Volltext: dx.doi.org/
-
Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) : Survival analysis from NAPOLI-1In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii250 - viii251Online Volltext: dx.doi.org/ (Open Access)
-
NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii249 - viii250Online Volltext: dx.doi.org/ (Open Access)
-
Notch-induced myeloid reprogramming in spontaneous pancreatic ductal adenocarcinoma by dual genetic targetingIn: Cancer Research Jg. 78 (2018) Nr. 17, S. 4997 - 5010Online Volltext: dx.doi.org/ (Open Access)
-
PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSIIn: Biochimica et Biophysica Acta (BBA) - General Subjects Jg. 1862 (2018) Nr. 1, S. 51 - 60Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
PICCA study : panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO studyIn: European Journal of Cancer (EJC) Jg. 92 (2018) S. 11 - 19Online Volltext: dx.doi.org/
-
Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trialIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 5, S. v42Online Volltext: dx.doi.org/ (Open Access)
-
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1 : Expanded analysis of a global phase 3 trialIn: European Journal of Cancer (EJC) Jg. 105 (2018) S. 71 - 78Online Volltext: dx.doi.org/ (Open Access)
-
The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapyIn: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 5, S. v42Online Volltext: dx.doi.org/ (Open Access)
-
Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinomaIn: Scientific Reports Jg. 7 (2017) 10.1038/s41598-017-16826-zOnline Volltext: dx.doi.org/ (Open Access)
-
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)In: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5, -
-
Co-clinical assessment of tumor cellularity in pancreatic cancerIn: Clinical Cancer Research Jg. 23 (2017) Nr. 6, S. 1461 - 1470Online Volltext: dx.doi.org/
-
Context-Dependent Epigenetic Regulation of Nuclear Factor of Activated T Cells 1 in Pancreatic PlasticityIn: Gastroenterology Jg. 152 (2017) Nr. 6, S. 1507 - 1520.e15Online Volltext: dx.doi.org/ (Open Access)
-
Epigenetic treatment of pancreatic cancer : Is there a therapeutic perspective on the horizon?In: Gut Jg. 66 (2017) Nr. 1, S. 168 - 179Online Volltext: dx.doi.org/ (Open Access)
-
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancerIn: British Journal of Cancer (BJC) Jg. 116 (2017) Nr. 11, S. 1462 - 1469Online Volltext: dx.doi.org/ (Open Access)
-
Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent mannerIn: Nucleic Acids Research Jg. 45 (2017) Nr. 11, S. 6334 - 6349Online Volltext: dx.doi.org/ (Open Access)
-
Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) geneIn: OncoTarget Jg. 8 (2017) Nr. 20, S. 33393 - 33404Online Volltext: dx.doi.org/ (Open Access)
-
Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung CancerIn: Neoplasia: An International Journal for Oncology Research Jg. 19 (2017) Nr. 1, S. 8 - 16Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Knockdown of myeloid cell hypoxia-inducible factor-1α ameliorates the acute pathology in DSS-induced colitisIn: PLoS ONE Jg. 12 (2017) Nr. 12, S. e0190074Online Volltext: dx.doi.org/ (Open Access)
-
Oncogenic KRas-induced Increase in Fluid-phase Endocytosis is Dependent on N-WASP and is Required for the Formation of Pancreatic Preneoplastic LesionsIn: EBioMedicine Jg. 15 (2017) S. 90 - 99Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Prognostic value of baseline neutrophil-to-lymphocyte ratio for predicting clinical outcome in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients treated with liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV alonIn: Annals of Oncology Jg. 28 (2017) Nr. Suppl. 5,
-
Quality-adjusted survival with combination nal-IRIFU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy : a Q-TWiST analysisIn: British Journal of Cancer (BJC) Jg. 116 (2017) Nr. 10, S. 1247 - 1253Online Volltext: dx.doi.org/ (Open Access)
-
Final results of NAPOLI-1 : A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapyIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 622PDOnline Volltext: dx.doi.org/
-
Gemcitabine impairs tumor perfusion in stroma rich murine endogenous PDACIn: European Journal of Cancer (EJC) Jg. 69 (2016) Nr. Suppl. 1, S. S67 - S68Online Volltext: dx.doi.org/
-
Hes1 Controls Exocrine Cell Plasticity and Restricts Development of Pancreatic Ductal Adenocarcinoma in a Mouse ModelIn: The American Journal of Pathology Jg. 186 (2016) Nr. 11, S. 2934 - 2944Online Volltext: dx.doi.org/
-
Identification of metabolic changes in Pancreatic Ductal AdenocarcinomaIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 76 - 77
-
Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cellsIn: Oncogene Jg. 35 (2016) Nr. 29, S. 3880 - 3886Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Membranous CD24 drives the epithelial phenotype of pancreatic cancerIn: OncoTarget Jg. 7 (2016) Nr. 31, S. 49156 - 49168Online Volltext: dx.doi.org/ (Open Access)
-
Modeling therapy response and spatial tissue distribution of erlotinib in pancreatic cancerIn: Molecular Cancer Therapeutics Jg. 15 (2016) Nr. 5, S. 1145 - 1152Online Volltext: dx.doi.org/ (Open Access)
-
Next-generation metabolic imaging in pancreatic cancerIn: Gut Jg. 65 (2016) Nr. 3, S. 367 - 369Online Volltext: dx.doi.org/
-
RAC1 activity is necessary for the development of murine undifferentiated PDACIn: European Journal of Cancer (EJC) Jg. 69 (2016) Nr. Suppl. 1, S. 140Online Volltext: dx.doi.org/
-
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER studyIn: Journal of Hepatology Jg. 65 (2016) Nr. 2, S. 280 - 288Online Volltext: dx.doi.org/
-
Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1 : A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapyIn: Annals of Oncology Jg. 27 (2016) Nr. Suppl. 6, S. 693POnline Volltext: dx.doi.org/
-
γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targetsIn: OncoTarget Jg. 7 (2016) Nr. 39, S. 62799 - 62813Online Volltext: dx.doi.org/ (Open Access)
-
PERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer : a translational subgroup analysis from AIO-PK0104In: BMC Cancer Jg. 14 (2014) Nr. 1, S. 624Online Volltext: dx.doi.org/ (Open Access)
-
Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104)In: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 4 Suppl., S. 189Online Volltext: dx.doi.org/
-
Resminostat in advanced hepatocellular carcinoma (HCC) : Overall survival subgroup analysis of prognostic factors in the SHELTER trialIn: Journal of Clinical Oncology (JCO) Jg. 31 (2013) Nr. 15 Suppl., S. e15088Online Volltext: dx.doi.org/
-
S3-Leitlinie zum exokrinen PankreaskarzinomIn: Zeitschrift für Gastroenterologie Jg. 51 (2013) Nr. 12, S. 1395 - 1440Online Volltext: dx.doi.org/
-
EGF Receptor Is Required for KRAS-Induced Pancreatic TumorigenesisIn: Cancer Cell Jg. 22 (2012) Nr. 3, S. 304 - 317Online Volltext: dx.doi.org/ (Open Access)
-
MALDI imaging mass spectrometry for in situ proteomic analysis of preneoplastic lesions in pancreatic cancerIn: PLoS ONE Jg. 7 (2012) Nr. 6, S. e39424Online Volltext: dx.doi.org/ (Open Access)
-
An inducible Tet-Off-H2B-GFP lentiviral reporter vector for detection and in vivo isolation of label-retaining cellsIn: Experimental Cell Research Jg. 316 (2010) Nr. 11, S. 1885 - 1895Online Volltext: dx.doi.org/
-
Identification of epidermal pdx1 expression discloses different roles of notch1 and notch2 in murine krasG¹²D-induced skin carcinogenesis in vivoIn: PLoS ONE Jg. 5 (2010) Nr. 10, S. e13578Online Volltext: dx.doi.org/ (Open Access)
-
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinomaIn: Proceedings of the National Academy of Sciences of the United States of America Jg. 107 (2010) Nr. 30, S. 13438 - 13443Online Volltext: dx.doi.org/ (Open Access)
-
Pancreatic cancer transcriptomes : molecular stratification in the adjuvant settingIn: Annals of Oncology Jg. 32 (2021) Nr. 2, S. 133 - 135Online Volltext: dx.doi.org/ (Open Access)
-
Evolutionary and immune microenvironment dynamics determine response to neoadjuvant treatment of oesophageal adenocarcinoma
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology Jg. 35 (2024) Nr. Supplement 1, S. S168 - S169Online Volltext: dx.doi.org/ -
Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology Jg. 35 (2024) Nr. Supplement 1, S. S155Online Volltext: dx.doi.org/ -
Homologous recombination repair (HRR) deficiency in biliary tract cancers : Clinical implications in subsequent therapy lines and correlation with platinum sensitivity
ESMO Gastrointestinal Cancers Congress 2024, 26-29 June 2024, Munich, Germany,In: Annals of Oncology Jg. 35 (2024) Nr. Supplement 1, S. S127Online Volltext: dx.doi.org/ -
68Ga-FAPI PET/CT novel diagnostic tool in sarcoma
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S415Online Volltext: dx.doi.org/ (Open Access) -
68Ga-FAPI-46 PET for imaging of FAP expressing cancer - interim findings from a single-center prospective interventional single-arm clinical trialIn: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P706
-
Changes in the course of advanced pancreatic cancer treatment with systemic chemotherapy : A pooled analysis of five clinical trials from two decades of clinical research within the German AIO Study-Group
ESMO 25th World Congress on Gastrointestinal Cancer 2023, 28 June - 1 July 2023, Barcelona, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 1: Abstract Book of the ESMO 25th World Congress on Gastrointestinal Cancer 2023, Barcelona, Spain, 28 June - 1 July 2023, S. S164Online Volltext: dx.doi.org/ (Open Access) -
Fibroblast activation protein alpha (FAPα) directed imaging and radioligand therapy in patients with solitary fibrous tumor (SFT)In: Journal of Nuclear Medicine (JNM) Jg. 64 (2023) Nr. Suppl. 1, P714
-
Head-to-head comparison of68Ga-FAPI46 PET/CT,18F-FDG PET/CT, and contrast- enhanced CT in patient with various solid tumors
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. 166 - S167Online Volltext: dx.doi.org/ (Open Access) -
Molecular characterization of biliary tract cancer at a single comprehensive cancer center focusing on DNA damage repair genes
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 62Online Volltext: dx.doi.org/ (Open Access) -
Occurence of hematotoxic side effects during 90Y-FAPI-46 radioligand therapy (RLT) in patients with advanced metastatic tumor diseases
Annual Congress of the European Association of Nuclear Medicine, 9-13 September 2023 Vienna, Austria,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 50 (2023) Nr. 1 supplement, S. S671Online Volltext: dx.doi.org/ (Open Access) -
Im Plasma zirkulierende zellfreie mRNA ermöglicht die minimal-invasive und Genotyp-unabhängige Therapieüberwachung bei Patienten mit Melanom
32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover, Germany,In: Journal der Deutschen Dermatologischen Gesellschaft (JDDG) Jg. 20 (2022) Nr. S3, S. 12 - 13Online Volltext: dx.doi.org/ -
P-5 Phase II study (daNIS-1) of the anti-TGF-β monoclonal antibody (mAb) NIS793 +/- spartalizumab in combination with nab-paclitaxel/gemcitabine (NG) versus NG alone in patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 4, S. 247Online Volltext: dx.doi.org/ (Open Access)
-
Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring DNA repair deficiencies
Annual Meeting of the European-Society-for-Medical-Oncology (ESMO): SEP 09-13, 2022; Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S762 - S763Online Volltext: dx.doi.org/ (Open Access) -
Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities
ESMO Congress 2022, 9 - 13 September 2022, Paris, France,In: Annals of Oncology Jg. 33 (2022) Nr. Supplement 7: Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022, S. S1231 - S1232Online Volltext: dx.doi.org/ (Open Access) -
Selective elimination of CD133+ cancer stem cells using novel BET/HDAC inhibitor TW09 as therapy for pancreatic ductal adenocarcinoma (PDAC)In: Annals of Oncology Jg. 33 (2022) Nr. Suppl. 8, S. 1411Online Volltext: dx.doi.org/ (Open Access)
-
Superiority of [68Ga]Ga-FAPI-46 over [18F]F-FDG PET/CT for cholangiocarcinoma imaging
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022 Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S192 - S193Online Volltext: dx.doi.org/ (Open Access) -
Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities
EANM‘22 ; 35th Annual Congress of the European Association of Nuclear Medicine ; October 15-19, 2022, Barcelona, Spain,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 49 (2022) Nr. Supplement 1, S. S119 - S120Online Volltext: dx.doi.org/ (Open Access) -
A novel theranostic approach for sarcoma : Insights on diagnostic and therapeutic use of FAP-radioligands
Gemeinsame Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 01.-04. Oktober 2021, Hybrid-Kongress,In: Oncology Research and Treatment Jg. 44 (2021) Nr. Supplement 2, S. 11 - 12Online Volltext: dx.doi.org/ (Open Access) -
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in previously untreated patients with metastatic uveal melanomaIn: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 855Online Volltext: dx.doi.org/ (Open Access)
-
Ga-68-FAPI for sarcoma imaging : Data from the FAPI-PET prospective observational trialIn: Journal of Nuclear Medicine (JNM) Jg. 62 (2021) Nr. Suppl. 1, 126
-
Initial clinical experience with [Y-90]Y-FAPI-46 radioligand therapy for advanced stage solid tumorsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 48 (2021) Nr. Suppl. 1, S. 290
-
Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multi-agent induction chemotherapy : Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)In: Annals of Oncology Jg. 32 (2021) Nr. Suppl. 5, S. 1091Online Volltext: dx.doi.org/ (Open Access)
-
RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer : Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316)In: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 15_Suppl, S. 3566 - 3566Online Volltext: dx.doi.org/
-
Comprehensive genomic analysis of rare cancers : Results of the MASTER precision oncology trial of the German Cancer Consortium
AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, USA,In: Cancer Research Jg. 80 (2020) Nr. Suppl. 16, S. 821Online Volltext: dx.doi.org/ -
Correlation of molecular profiles with response to targeted drugs in pancreatic cancer modelsIn: European Journal of Cancer (EJC) Jg. 138, Supplement 2 (2020) S. S58 - S59Online Volltext: dx.doi.org/
-
Growth factor independence 1 expression induced metabolic vulnerabilities and presents novel therapeutic opportunities in acute myeloid leukemia
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 43 - 44Online Volltext: dx.doi.org/ (Open Access) -
Interim safety analysis of the phase IIb study of ramucirumab in combination with TAS102 vs. TAS102 monotherapy in metastatic colorectal cancer : The RAMTAS trial of the German AIOIn: Annals of Oncology Jg. 31 (2020) Nr. Suppl. 4, S. S427 - S428Online Volltext: dx.doi.org/ (Open Access)
-
A phase IIb study of ramucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic, chemotherapy refractory colorectal cancer patients : The RAMTAS trial of the German AIO (KRK-0316)In: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. TPS3617 - TPS3617Online Volltext: dx.doi.org/
-
Anti-leukemic activity through CDK9 inhibition in T-cell prolymphocytic leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 218Online Volltext: dx.doi.org/ (Open Access) -
Clinical relevance of comprehensive genomic analysis in advanced-stage cancers and rare malignancies : Results from the MASTER trial of the German Cancer ConsortiumIn: Cancer Research Jg. 79 (2019) Nr. Suppl. 13,Online Volltext: dx.doi.org/
-
PET-directed combined modality therapy for gastroesophageal junction cancer : First results of the prospective MEMORI trialIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 15, S. 4018 - 4018Online Volltext: dx.doi.org/
-
Advanced organoid culture technology in pancreatic cancer and its translational applications
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 206Online Volltext: dx.doi.org/ (Open Access) -
CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT-PMO-1601)
33. Deutscher Krebskongress - Perspektiven verändern Krebs - Krebs verändert Perspektiven. Diagnose - Therapie - (Über-)Leben ; 21.-24. Februar 2018, Berlin,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 1, S. 156Online Volltext: dx.doi.org/ (Open Access) -
Metabolic heterogeneity as a PET-biomarker predicts overall survival of pancreatic cancer patientsIn: European Journal of Nuclear Medicine and Molecular Imaging Jg. 45 (2018) Nr. Suppl. 1, S. 97Online Volltext: dx.doi.org/ (Open Access)
-
Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancer
30th EORTC – NCI – AACR Symposium; 13 Nov - 16 Nov 2018; Dublin, Ireland,In: European Journal of Cancer (EJC) Jg. 103 (2018) Nr. Supplement 1, S. E101Online Volltext: dx.doi.org/ -
Preclinical evaluation of novel treatment strategies in patient-derived xenograft (PDX) models of pancreatic cancerIn: Cancer Research Jg. 78 (2018) Nr. Suppl. 13,Online Volltext: dx.doi.org/ (Open Access)
-
Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 5, S. v41 - v42Online Volltext: dx.doi.org/ (Open Access)
-
Secondary resectability in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- versus FOLFIRINOX-based induction chemotherapy : Interim results of a randomized phase II AIO trial (NEOLAP)In: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 4_suppl, S. 348 - 348Online Volltext: dx.doi.org/ (Open Access)
-
Subgroup analysis by baseline (BL) weight-associated parameters : A phase III study of liposomal irinotecan (nal-IRI)+/--5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 4, S. 410Online Volltext: dx.doi.org/ (Open Access)
-
Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1 : A phase III study of liposomal irinotecan (nal IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) pIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 4, S. 379Online Volltext: dx.doi.org/ (Open Access)
-
Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1 : A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic panIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. Suppl. 4, S. 460Online Volltext: dx.doi.org/ (Open Access)
-
The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)In: Annals of Oncology Jg. 29 (2018) Nr. Suppl. 8, S. viii255 - viii256Online Volltext: dx.doi.org/ (Open Access)
-
Co-clinical assessment of tumor cellularity in pancreatic cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 175Online Volltext: dx.doi.org/ -
Effects of nanoliposomal irinotecan (nal-IRI;MM-398) +/- 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1 : a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-bIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 259Online Volltext: dx.doi.org/
-
Expanded analyses of NAPOLI-1 : Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based the
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; Berlin, 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 170Online Volltext: dx.doi.org/ -
Patient-derived organoids to model intra- and intertumoral heterogeneity of pancreatic cancer in high-throughput drug screens
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 162Online Volltext: dx.doi.org/ -
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with geIn: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 3, S. 260Online Volltext: dx.doi.org/
-
Targeting notch for myeloid reprogramming in pancreatic cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 16Online Volltext: dx.doi.org/ -
Use of Diffusion-weighted magnetic resonance imaging for therapy response evaluation in pancreatic cancer
Krebsmedizin heute: präventiv, personalisiert, präzise und partizipativ ; 32. Deutscher Krebskongress ; 24.-27. Februar 2016, Berlin,In: Oncology Research and Treatment Jg. 39 (2016) Nr. Suppl. 1, S. 113 - 114Online Volltext: dx.doi.org/ -
Na-Folfiri plus sunitinib versus Na-Folfiri alone in advanced chemorefractory esophagogastric cancer patients : A randomized double-blinded placebo-controlled multicentric AIO phase II trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie, 18.-22. Oktober 2013, Wien, Österreich,In: Onkologie Jg. 36 (2013) Nr. Suppl. 7, S. 74Online Volltext: dx.doi.org/ -
Clinical update on the phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC) - The Shelter Study
13th World Congress on Gastrointestinal Cancer 22–25 June 2011, Barcelona, Spain,In: Annals of Oncology Jg. 22 (2011) Nr. Suppl. 5, S. v76 - v76Online Volltext: dx.doi.org/ -
DNA damage repair pathways in biliary tract cancer : A new target for precision medicine?
ESMO Congress 2023 ; 20 - 24 October 2023, Madrid, Spain,In: Annals of Oncology Jg. 34 (2023) Nr. Supplement 2: Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023, S. S223Online Volltext: dx.doi.org/ (Open Access) -
Analyse zweier prospektiver klinischer Studien der Arbeitsgemeinschaft Internistische Onkologie mit der “Burden of Therapy” (BOTh®TM) Methode : einem neuen Instrument zur Evaluation unerwünschter Ereignisse beim metastasierten Pankreaskarzinom
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 295Online Volltext: dx.doi.org/ (Open Access)